The review by Li, Zhu, Shen and colleagues examines two main routes for producing therapeutic immune cells. The first begins with peripheral blood mononuclear cells, a mixed population that includes lymphocytes and monocytes collected from a patient or donor. These cells can be isolated, activated and genetically modified before being returned to the recipient. The second route uses stem cells as a renewable starting material. Haematopoietic stem cells, which naturally generate blood and immune cells, can be expanded or redirected, while pluripotent stem cells can be differentiated into specialized immune populations under controlled laboratory conditions.

This distinction is important because conventional autologous cell therapies are laborious and variable. In an autologous process, a patient’s cells are collected, engineered and expanded before treatment. Disease, age, prior therapies and the condition of the patient’s immune system can all affect the quality and quantity of the starting material. Allogeneic manufacturing instead uses cells from a donor or a banked stem-cell line. A single engineered cell source may therefore be used to produce multiple treatment doses, allowing manufacturing to be performed in advance and under tightly controlled conditions.

Stem-cell engineering has expanded the range of immune cells that can be produced for therapy. T cells remain a central focus because they can identify abnormal cells through antigen-specific receptors and destroy them through cytotoxic mechanisms. Natural killer cells provide another route to immune-mediated killing and can recognize stressed or transformed cells without relying on the same antigen-recognition system as conventional T cells. Macrophages, which engulf material and influence inflammation, are also being developed as therapeutic agents. Each cell type offers distinct biological advantages, but each presents different challenges in generating a stable, potent and clinically useful product.

One of the most prominent technologies discussed in this field is the chimeric antigen receptor, or CAR. A CAR is a synthetic receptor introduced into an immune cell through genetic engineering. Its external binding region is designed to recognize a selected molecular marker, while internal signalling domains activate the cell after target engagement. CAR engineering has been particularly influential in T-cell therapy, but researchers are also adapting the technology for natural killer cells and macrophages. These CAR-equipped cells are intended to improve target recognition, strengthen activation and potentially overcome mechanisms that allow diseased cells to evade natural immunity.

Genetic modification can also be used to improve safety and immune compatibility. Researchers are investigating edits that reduce the ability of donor-derived cells to attack healthy recipient tissues, a complication associated with immune recognition across individuals. Other modifications may limit the capacity of therapeutic cells to trigger excessive inflammation, a process that can produce serious systemic effects. Gene engineering can additionally introduce “safety switches” or other control systems designed to eliminate or deactivate the cells if unwanted toxicity occurs. At the same time, reducing the expression of molecules recognized by the recipient’s immune system may help prolong the survival of transplanted cells.

The review also highlights the importance of differentiation platforms. Producing an immune cell from a stem cell is not simply a matter of adding one factor to a culture. Cells must receive carefully timed combinations of signalling molecules, growth factors and environmental cues that reproduce aspects of blood-cell development. Scientists are refining three-dimensional culture systems, feeder-free methods and scalable bioreactors to control this process. The objective is to generate large numbers of cells with a uniform identity, predictable function and minimal contamination by unwanted or incompletely differentiated cell types.

Manufacturing remains one of the field’s decisive tests. A clinically compatible process must preserve cell viability and activity while meeting strict standards for sterility, genetic stability and product consistency. Cells may need to be frozen, transported and stored without losing their therapeutic properties. Stem-cell-derived products also require extensive characterization to confirm that residual undifferentiated cells do not create safety risks. Advances in automation, closed-system processing and analytical technologies are helping researchers move from small laboratory batches toward reproducible production at a scale suitable for clinical use.

Early clinical evidence is beginning to shape expectations, but the review emphasizes that important questions remain. Researchers must determine how long engineered cells persist in the body, whether they continue functioning after repeated exposure to disease environments and how reliably they reach the tissues where they are needed. Tumours and chronic inflammatory conditions can suppress immune activity, while infectious diseases may impose rapidly changing biological pressures. Future studies will need to compare cell sources, genetic designs and manufacturing strategies directly, while also monitoring delayed toxicities and the long-term consequences of genome editing.

Together, these developments suggest that allogeneic immunotherapy could become a flexible platform rather than a single treatment type. Donor-derived and stem-cell-derived T cells, natural killer cells, macrophages and CAR-engineered variants may eventually be selected according to the disease, target and desired immune response. The review presents this convergence of gene engineering, stem-cell biology and bioprocessing as a foundation for more accessible cellular medicines. Its central message is that therapeutic success will depend not only on making immune cells powerful, but also on making them controllable, compatible, manufacturable and safe enough for broad clinical application.

Subject of Research: Allogeneic immunotherapy using genetically engineered and stem-cell-derived immune cells

Article Title: Allogeneic immunotherapy

Article References: Li, YR., Zhu, Y., Shen, X. et al. Allogeneic immunotherapy. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00468-w

Image Credits: AI Generated

DOI: 10.1038/s44222-026-00468-w

Keywords: Allogeneic immunotherapy, cell-based immunotherapy, stem cell engineering, T cells, natural killer cells, macrophages, CAR-engineered cells, gene editing, pluripotent stem cells, therapeutic cell manufacturing

Pancreatic ductal adenocarcinoma ranks among the most lethal cancers globally, characterized by a dismal five-year survival rate hovering near 10 percent. Conventional treatment paradigms — combining surgical resection, chemotherapy, and radiation therapy — continue to yield limited success, largely due to the disease’s aggressive biology and propensity for early metastasis. Moreover, immune checkpoint inhibitors, which have revolutionized therapy for several cancer types, exhibit scant efficacy in pancreatic tumors, largely because of the immunosuppressive tumor microenvironment and low mutational burden that render the cancer less recognizable to endogenous immune effectors.

Against this bleak backdrop, the MIT-Dana-Farber collaborative study leveraged a sophisticated immunopeptidomics workflow to profile the landscape of peptides presented on pancreatic tumor cell surfaces. This methodology extracts major histocompatibility complex (MHC)-bound peptides directly from tumor-derived organoids — three-dimensional in vitro constructs that faithfully replicate tumor architecture and heterogeneity — enabling mass spectrometry-based identification of thousands of previously uncharacterized antigens. Intriguingly, the predominant subset of these antigens was not derived from conventional protein-coding regions but from "cryptic" regions of the genome, encompassing sequences thought to be silent or non-coding under normal circumstances.

Detailed analyses across approximately twelve patient-derived pancreatic tumor samples revealed an average expression of roughly 250 cryptic peptides per tumor, culminating in an aggregate identification of about 1,700 distinct peptides. To ascertain their clinical relevance, the investigators performed an extensive comparative assessment against healthy tissue counterparts. This rigorous filtering identified approximately 500 cryptic peptides uniquely associated with malignant pancreatic cells, absent from an array of normal tissue types, thereby earmarking these peptides as compelling tumor-restricted targets.

Capitalizing on these findings, the team designed and synthesized select peptide epitopes to ascertain their immunogenic potential. Within a controlled in vitro environment, immature T cells exposed to these cryptic antigens exhibited robust clonal expansion against nearly half of the tested peptides, indicating strong T cell receptor (TCR) engagement and functional activation. Subsequently, T cells were genetically engineered to express TCRs specific for these cryptic peptides, enabling precise recognition and targeting of pancreatic tumor cells expressing the cryptic antigens.

The functional potency of these engineered T cells was demonstrated in both organoid cultures and murine models. In organoid assays reflective of patient tumor biology, the cryptic peptide-targeted T cells effectively induced cytotoxicity, reducing viable tumor cell populations significantly. Moreover, in vivo studies involving immunodeficient mice implanted with patient-derived tumor organoids displayed markedly slower tumor progression following treatment with the engineered T cells, affirming the translational promise of this immunotherapeutic strategy.

While the engineered T cells did not achieve complete tumor eradication in these preclinical models, the pronounced inhibitory effect on tumor growth portends substantial clinical benefits, particularly if combined with adjunctive strategies to bolster T cell persistence and functionality. The researchers anticipate that further optimization of TCR affinity and combinatorial regimens may amplify therapeutic efficacy against this notoriously resistant cancer.

Beyond cellular therapies, the discovery of cryptic peptides as tumor-specific antigens also provides a robust framework for the development of vaccine platforms. Investigators are actively exploring vaccine formulations encompassing epitopes frequently detected across multiple patient tumors, aiming to prime endogenous T cells against these cryptic targets. Such vaccines hold the promise of stimulating an immune response capable of surveilling and eradicating pancreatic tumor cells systemically.

Furthermore, the implications of this research extend into the realm of bispecific T cell engagers — engineered antibody constructs that physically link T cells to tumor antigens, enabling targeted cytotoxicity without the need for genetic engineering of immune cells. Cryptic peptide-targeted engagers could offer a versatile off-the-shelf therapeutic option catering to a broader patient population.

This paradigm-shifting study thus harnesses the proteogenomic complexity of pancreatic cancers to uncover a previously untapped antigenic repertoire, paving the way for next-generation immunotherapies tailored to the unique molecular signature of pancreatic tumors. Clinical translation, while still in nascent stages, is anticipated within several years, with ongoing efforts aimed at enhancing the safety, specificity, and efficacy of cryptic peptide-targeted approaches.

Supported by a constellation of cancer-focused funding bodies—including the Hale Family Center for Pancreatic Cancer Research, the Lustgarten Foundation, Stand Up To Cancer, and the National Institutes of Health—the study exemplifies the synergistic integration of genomic, proteomic, and immunological expertise. As such, it stands as a beacon of hope for improving outcomes in pancreatic cancer, a malignancy that has long resisted conventional and immune-based therapies.

In summary, the identification of pancreatic cancer-restricted cryptic antigens challenges the existing dogma of cancer immunology and opens an innovative path for personalized T cell therapies and vaccine development. By exploiting the hidden layers of the tumor’s antigenic landscape, this approach may ultimately tip the balance in favor of durable immune-mediated tumor control and improved patient survival in pancreatic cancer.

Subject of Research: Pancreatic cancer-restricted cryptic peptides as targets for T cell recognition and immunotherapy

Article Title: Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition

News Publication Date: 8-May-2025

Web References: DOI: 10.1126/science.adk3487

Keywords: Pancreatic cancer, cryptic peptides, immunopeptidomics, T cell therapy, cancer immunotherapy, cell transfer therapy, peptides, cell therapies, cancer treatments, vaccine research, cancer research